...
首页> 外文期刊>European archives of oto-rhino-laryngology: Official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) >Hearing outcome does not depend on the interval of intratympanic steroid administration in idiopathic sudden sensorineural hearing loss
【24h】

Hearing outcome does not depend on the interval of intratympanic steroid administration in idiopathic sudden sensorineural hearing loss

机译:在特发性突然感觉神经性听力减退中,听力结果不取决于鼓膜内给予类固醇的间隔

获取原文
获取原文并翻译 | 示例
           

摘要

We studied the effect of intratympanic steroid administration with different intervals on hearing outcomes in patients with idiopathic sudden sensorineural hearing loss (ISSNHL). The subjects were 197 consecutive patients (197 ears) with ISSNHL (hearing level aeyen40 dB, interval between onset and treatment aecurrency sign30 days). They received systemic administration of prednisolone (100 mg followed by tapered doses) combined with intratympanic injection of dexamethasone (4 mg/ml). Intratympanic injection was performed once a week for 4 weeks in 105 patients (long-interval group), or 4 times in 1 week in 92 patients (short-interval group). The hearing outcomes were evaluated at two points of time: 1 week from the start of treatment, and 1-2 months after the completion of treatment when the hearing level reached a plateau. There was no significant difference in the cure rate, marked-recovery rate, recovery rate, hearing gain, hearing level, or percent hearing improvement between the long- and short-interval groups at either point of time. Multiple regression analysis also showed that the final hearing level did not depend on the interval of intratympanic steroid injection. These results indicate that the hearing outcome of ISSNHL does not improve even if the interval of intratympanic injection is shortened. This implies that a lower total number of intratympanic steroid injections may be as effective as the present protocol.
机译:我们研究了不同间隔的鼓膜内给予类固醇激素对特发性突然感觉神经性听力损失(ISSNHL)患者听力结果的影响。受试者为197例ISSNHL连续患者(197耳)(听力水平aeyen40 dB,发作与治疗并发迹象之间的间隔30天)。他们接受了泼尼松龙的全身性给药(100 mg,然后逐渐给药),并在鼓室内注射地塞米松(4 mg / ml)。 105例患者(长间隔组)每周进行一次鼓膜内注射,持续4周,而92例患者(短间隔组)中,每周一次进行鼓膜内注射,每次4次。在两个时间点评估听力结果:从治疗开始1周,以及治疗结束后1-2个月听力水平达到平稳时。长间隔和短间隔组在任何时间点的治愈率,明显恢复率,恢复率,听力增益,听力水平或听力改善百分比均无显着差异。多元回归分析还显示,最终的听力水平不取决于鼓膜内注射类固醇的间隔。这些结果表明,即使缩短鼓膜内注射的间隔,ISSNHL的听力结果也不会改善。这意味着更少的鼓膜内类固醇注射总数可以与本方案一样有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号